Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Medical Genetics · Ectodermal Dysplasia

What Does a VUS Result Mean for Ectodermal Dysplasia?

At a Glance

A Variant of Uncertain Significance (VUS) means a genetic change was found, but scientists aren't sure if it causes ectodermal dysplasia or is harmless. A VUS shouldn't be used for medical decisions. Contact your genetic counselor every 1 to 2 years to see if the variant has been reclassified.

In this answer

2 sections

01

Understanding Your VUS Result

02

What Are Your Next Steps?

A Variant of Uncertain Significance (VUS) means that your genetic test found a change in a gene associated with ectodermal dysplasia (such as EDA, EDAR, or WNT10A), but scientists and doctors do not yet have enough information to know if this specific change causes the condition or if it is just a normal, harmless difference in your DNA [1][2]. Receiving a VUS is a very common result in genetic testing, especially as tests become more advanced and look at more genes [3]. It does not confirm a diagnosis of ectodermal dysplasia, nor does it completely rule one out.

Understanding Your VUS Result

To understand a VUS, it helps to think of your DNA as a massive instruction manual for your body. The genetic test acts like a spellchecker reading through the chapters related to ectodermal dysplasia.

  • A Pathogenic variant is like a spelling mistake that completely changes the meaning of a sentence, leading to a medical condition.
  • A Benign variant is like using the British spelling “colour” instead of the American “color”—it looks different, but the meaning is exactly the same and it causes no health issues.
  • A Variant of Uncertain Significance (VUS) means the spellchecker found a new word or a typo, but the scientific community hasn’t seen it enough times to know whether it changes the meaning of the instruction manual [1][4].

Because ectodermal dysplasias are rare conditions, it is not unusual for genetic tests to uncover variants that have never been seen before, or have only been seen in a few people [5]. Currently, medical guidelines state that a VUS should not be used on its own to make medical, surgical, or family planning decisions [6][2]. Your doctors will still rely heavily on your physical symptoms—like missing teeth, sparse hair, or sweating issues—to guide your care [7].

What Are Your Next Steps?

While a VUS can feel frustrating and uncertain, there are clear, actionable steps you can take to manage this result and potentially help scientists figure out what your specific variant means [8].

1. Speak with a Genetic Counselor

A genetic counselor is a healthcare professional trained to help you understand genetic test results. They will look at your VUS in the context of your specific physical symptoms and your family’s medical history [7][9]. They can help interpret the lab report, explain what the variant might mean for you, and ensure that the uncertainty of the result doesn’t lead to unnecessary anxiety or incorrect medical procedures [10][11].

2. Consider Family Testing (Segregation Analysis)

One of the most powerful ways doctors figure out if a VUS causes ectodermal dysplasia is to test other members of your family [12]. This is called familial segregation analysis [13].
If you have family members who also have symptoms of ectodermal dysplasia, testing them to see if they share the exact same VUS can provide strong clues [14]. If the variant always appears in family members with the condition and is absent in those without symptoms, scientists are closer to classifying it as a pathogenic (disease-causing) variant [15][16].

Note: Insurance coverage for family testing can be complicated. Ask your genetic counselor about cost, as some laboratories offer free or discounted testing programs for family members when trying to understand a VUS.

3. Check Back in 1 to 2 Years

The classification of a VUS is not always permanent. Genetics is a rapidly evolving field, and a VUS is frequently reclassified over time as more people are tested worldwide and researchers learn more [17][18]. Fortunately, when a VUS is eventually reclassified, the vast majority are found to be harmless, normal variations (benign) rather than disease-causing [17].

It is highly recommended that you or your doctor contact the genetic testing laboratory or your genetic counselor every 1 to 2 years to ask if there has been any update or reclassification regarding your specific variant [18][19]. While clinics try their best, they do not always have the resources to automatically notify you if a change occurs, so it is important to be proactive [20][21].

4. Consider Patient Registries and Advocacy Groups

Living in the “limbo” of a VUS can feel isolating. Connecting with advocacy organizations, such as the National Foundation for Ectodermal Dysplasias (NFED), can provide emotional support and resources [22]. Additionally, you might consider asking your counselor about joining a patient registry (like GenomeConnect or MyGene2). By securely submitting your symptoms and genetic data, you directly contribute to the global databases researchers use to finally classify variants [22][23].

Common questions in this guide

What does a Variant of Uncertain Significance (VUS) mean?
A VUS means your genetic test found a change in your DNA, but scientists do not yet have enough data to know if it causes ectodermal dysplasia or is just a normal, harmless variation. It does not confirm or rule out a diagnosis.
Can a VUS result be used to make medical decisions?
No, current medical guidelines state that a VUS should not be used on its own to make medical, surgical, or family planning decisions. Instead, your doctors will rely heavily on your physical symptoms to guide your medical care.
Should my family members get genetic testing if I have a VUS?
Yes, testing family members who have similar physical symptoms can help determine if the VUS causes the condition. If the variant only appears in family members with symptoms, it provides strong clues for scientists to reclassify it.
Will my VUS genetic test result ever be reclassified?
Yes, genetic variants are frequently reclassified as researchers learn more from testing people worldwide. When a VUS is reclassified, the vast majority are found to be harmless. You should contact your genetic counselor every 1 to 2 years to check for updates.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you write down the exact name of the gene and the specific variant I have so I can keep it in my personal records?
  2. 2.Is the laboratory that performed my test currently offering any free or discounted testing programs for my family members?
  3. 3.Given my physical symptoms, do you suspect this variant is causing my condition, or should we be looking for other answers?
  4. 4.Who in this clinic should I contact in 12 to 24 months to check if my variant has been reclassified?
  5. 5.Are there any research registries or studies for ectodermal dysplasia that I could join to help scientists understand my variant?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

How to Keep a Child with Ectodermal Dysplasia CoolWhen to Get Dentures & Implants for Ectodermal DysplasiaWhat is the Difference Between Clouston Syndrome and HED?Do Female Carriers of XLHED Have Symptoms? ExplainedHow to Manage Dry Skin & Eyes in Ectodermal DysplasiaHow to Get Medical Insurance to Cover ED Dental ImplantsWhat Doctors Treat Ectodermal Dysplasia?Is There a Prenatal Treatment for XLHED?Why Do Infants With HED Get Unexplained Fevers?What Is Ectodermal Dysplasia Life Expectancy?

References

References (23)
  1. 1

    APP, PSEN1, and PSEN2 Variants in Alzheimer's Disease: Systematic Re-evaluation According to ACMG Guidelines.

    Xiao X, Liu H, Liu X, et al.

    Frontiers in aging neuroscience 2021; (13()):695808 doi:10.3389/fnagi.2021.695808.

    PMID: 34220489
  2. 2

    The Development and Evaluation of Novel Patient Educational Material for a Variant of Uncertain Significance (VUS) Result in Hereditary Cancer Genes.

    Cragun D, Dean M, Baker D, et al.

    Current oncology (Toronto, Ont.) 2024; (31(6)):3361-3378 doi:10.3390/curroncol31060256.

    PMID: 38920739
  3. 3

    Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study.

    Adam F, Fluri M, Scherz A, Rabaglio M

    BMC medical genomics 2023; (16(1)):7 doi:10.1186/s12920-023-01437-7.

    PMID: 36647026
  4. 4

    Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants.

    Lee K, Krempely K, Roberts ME, et al.

    Human mutation 2018; (39(11)):1553-1568 doi:10.1002/humu.23650.

    PMID: 30311375
  5. 5

    Novel homozygous frameshift insertion variant in the last exon of the EDARADD causing hypohidrotic ectodermal dysplasia in two siblings: case report and review of the literature.

    Kablan A, Tasdelen E

    Italian journal of pediatrics 2024; (50(1)):112 doi:10.1186/s13052-024-01681-2.

    PMID: 38840186
  6. 6

    First report of X-linked hypohidrotic ectodermal dysplasia with a hemizygous c.1142G > C in the EDA gene: variant of uncertain significance or new pathogenic variant?

    Tumminello M, Gangemi A, Matina F, et al.

    Italian journal of pediatrics 2021; (47(1)):128 doi:10.1186/s13052-021-01078-5.

    PMID: 34078430
  7. 7

    Impact of Variant Reclassification in Cancer Predisposition Genes on Clinical Care.

    Chiang J, Chia TH, Yuen J, et al.

    JCO precision oncology 2021; (5()):577-584 doi:10.1200/PO.20.00399.

    PMID: 34994607
  8. 8

    Role of psychological background in cancer susceptibility genetic testing distress: It is not only about a positive result.

    López-Fernández A, Villacampa G, Salinas M, et al.

    Journal of genetic counseling 2023; (32(4)):778-787 doi:10.1002/jgc4.1687.

    PMID: 36748747
  9. 9

    "I Don't Want to Be an Ostrich": Managing Mothers' Uncertainty during BRCA1/2 Genetic Counseling.

    Fisher CL, Roccotagliata T, Rising CJ, et al.

    Journal of genetic counseling 2017; (26(3)):455-468 doi:10.1007/s10897-016-9998-x.

    PMID: 27473644
  10. 10

    Elaboration of the Reciprocal-Engagement Model of Genetic Counseling Practice: a Qualitative Investigation of Goals and Strategies.

    Redlinger-Grosse K, Veach PM, LeRoy BS, Zierhut H

    Journal of genetic counseling 2017; (26(6)):1372-1387 doi:10.1007/s10897-017-0114-7.

    PMID: 28643080
  11. 11

    When Germline Genetic Testing Results Are Unclear: Highlighting Variants of Uncertain Significance.

    Kelly P, Mahon S, Friend P

    Journal of the advanced practitioner in oncology 2023; (14(7)):631-638 doi:10.6004/jadpro.2023.14.7.7.

    PMID: 38196669
  12. 12

    The uncertainty of copy number variants: pregnancy decisions and clinical follow-up.

    Shi P, Liang H, Hou Y, et al.

    American journal of obstetrics and gynecology 2023; (229(2)):170.e1-170.e8 doi:10.1016/j.ajog.2023.01.022.

    PMID: 36716986
  13. 13

    Parent-of-origin testing of prenatal copy number variations: a retrospective study of 167 family cases.

    Liu Y, Peng Y, Liang Z, Pan Q

    Scientific reports 2025; (15(1)):5979 doi:10.1038/s41598-025-86487-w.

    PMID: 39966468
  14. 14

    Whole Exome Sequencing and Molecular Modeling of a Missense Variant in TNFAIP3 That Segregates with Disease in a Family with Chronic Urticaria and Angioedema.

    Harris AL, Blackburn PR, Richter JE, et al.

    Case reports in genetics 2018; (2018()):6968395 doi:10.1155/2018/6968395.

    PMID: 29682366
  15. 15

    Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients.

    Henkel J, Laner A, Locher M, et al.

    European journal of human genetics : EJHG 2023; (31(8)):925-930 doi:10.1038/s41431-023-01380-2.

    PMID: 37188824
  16. 16

    Functional and clinical analysis of five EDA variants associated with ectodermal dysplasia but with a hard-to-predict significance.

    Gökdere S, Schneider H, Hehr U, et al.

    Frontiers in genetics 2022; (13()):934395 doi:10.3389/fgene.2022.934395.

    PMID: 35923710
  17. 17

    Diagnostic yield from cardiac gene testing for inherited cardiac conditions and re-evaluation of pre-ACMG variants of uncertain significance.

    Murphy J, Kirk CW, Lambert DM, et al.

    Irish journal of medical science 2024; (193(4)):1775-1785 doi:10.1007/s11845-024-03650-4.

    PMID: 38489124
  18. 18

    Variant reclassification and clinical implications.

    Walsh N, Cooper A, Dockery A, O'Byrne JJ

    Journal of medical genetics 2024; (61(3)):207-211 doi:10.1136/jmg-2023-109488.

    PMID: 38296635
  19. 19

    Exploring the Genetic Etiology of Pediatric Epilepsy: Insights from Targeted Next-Generation Sequence Analysis.

    Ozturk O, Ozturk M, Ates K, et al.

    Molecular syndromology 2025; (16(2)):115-127 doi:10.1159/000540762.

    PMID: 40176841
  20. 20

    Unrecognised actionability for breast cancer risk variants identified in a national-level review of Australian familial cancer centres.

    Fortuno C, Cops EJ, Davidson AL, et al.

    European journal of human genetics : EJHG 2024; (32(12)):1632-1639 doi:10.1038/s41431-024-01705-9.

    PMID: 39402389
  21. 21

    From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals.

    Augusto BM, Lake P, Scherr CL, et al.

    Journal of community genetics 2018; (9(3)):209-215 doi:10.1007/s12687-017-0343-3.

    PMID: 29124491
  22. 22

    Postpartum Presentation of a Variant of Uncertain Significance in COL3A1: A Case Report.

    Khamissi FZ, Bachur C, Palatnik A, et al.

    American journal of perinatology 2025; doi:10.1055/a-2722-8222.

    PMID: 41173024
  23. 23

    A Noncanonical Splice Variant in RTEL1 Responsible for Familial Pulmonary Fibrosis.

    White-Brown A, Marshall A, Wang X, et al.

    American journal of medical genetics. Part A 2026; (200(2)):475-480 doi:10.1002/ajmg.a.64267.

    PMID: 40985209

This page explains genetic testing terminology for educational purposes only. Your genetic counselor or healthcare provider is the best source for interpreting your specific VUS result and guiding your care.

Get notified when new evidence is published on Ectodermal dysplasia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.